John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.
John D. Hainsworth, MD
Advertisement
Articles by John D. Hainsworth, MD
Advertisement
Latest Updated Articles
Dr. Hainsworth on Selecting Therapy Based on GeneticsPublished: June 5th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5